Condition: Hepatocellular Carcinoma · Liver Cancer · Sponsor: Asan Medical Center
1. Research purpose To perform genomic and immune profiling analysis on blood and tissue samples obtained from blood sampling and tumor biopsy in patients with advanced hepatocellular carcinoma with immuno-oncology treatment. 2. Research Subject Patients who will receive immuno-oncology treatment in recurrent, metastatic, and advanced liver cancer, who meet the selection criteria of the study, do not have exclusion criteria, and voluntarily agree to participate in the study. 3. Number of study subjects 50 people 4. Research Method 1) In patients with advanced hepatocellular carcinoma, peripheral blood will be collected at baseline before treatment, 6 weeks, 12 weeks, 24 weeks, 48 weeks after treatment, and at the time of cancer progression. 2\) Fresh tumors will be stored in the tissue obtained during the biopsy to perform genetic analysis
This description comes directly from the study's public registry record.
Ju Hyun Shim · 0230103190 · s5854@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, Song-pa, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07186010